

Cancer Vaccines Market to Reach \$10.00 billion with 23.7% CAGR Forecast to 2022

Cancer Vaccines Market to Grow at a 23.7% CAGR Forecast to 2022

PUNE, INDIA, October 10, 2016

/EINPresswire.com/ -- Summery

According to researchers, the Global [Cancer Vaccines](#) market is accounted for \$2.25 billion in 2015 and is expected to reach \$10.00 billion by 2022 growing at a CAGR of 23.7%. Factors such as rising number of cancer patients, increasing ageing population and awareness of vaccines are fueling the market. However, less availability of vaccines and advanced treatments in underdeveloped regions may limit the market growth.

Request a sample report @

<https://www.wiseguyreports.com/sample-request/674315-cancer-vaccines-global-market-outlook-2016-2022>

North America accounted for the largest share in the market followed by Asia Pacific. The favourable growth is attributed to supportive government and other organisations such as World health organisation and GAVI initiatives.

Some of the key players in Global Cancer Vaccines market include Oxford BioMedica, Vaccinogen Inc., GlaxoSmithKline, Sanofi India Limited-P.P. Enterprises, Juvaris Biotherapeutics, Merk&co, Prima BioMed Ltd, Cytos Biotechnology AG, Ubivac, duro BioTech, AstraZeneca plc., and MedImmune, LLC.

Disease Indication Covered:

- Cervical cancer
- Esophageal cancer
- Liver cancer
- Prostate cancer
- Lung cancer
- Breast cancer
- Stomach cancer

Technologies Covered:

- Inactivated Vaccines
- Peptide/protein vaccines
- Synthetic Vaccines
- Toxoid Vaccines



- Live Attenuated Vaccines
- Recombinant Vector Vaccines
- Antigen vaccines
- Dendritic Cell Vaccines
- Subunit Vaccines
- Heat shock protein vaccines
- DNA- and vector-based vaccines
- Conjugate Vaccines
- Anti-idiotypic vaccines
- Cancer stem cell vaccines

End Users Covered:

- Adults
- Paediatrics

Vaccine Types Covered:

- Therapeutic Vaccines
- Preventive Vaccines

What our report offers:

- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=674315

Table of Contents

1 Executive Summary

2 Preface

2.1 Abstract

2.2 Stake Holders

2.3 Research Scope

2.4 Research Methodology

2.4.1 Data Mining

2.4.2 Data Analysis

2.4.3 Data Validation

2.4.4 Research Approach

2.5 Research Sources

2.5.1 Primary Research Sources

2.5.2 Secondary Research Sources

2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction

- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets

4 Porters Five Force Analysis

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 Global Cancer Vaccines Market, By Disease Indication

- 5.1 Introduction
- 5.2 Cervical cancer
- 5.3 Esophageal cancer
- 5.4 Liver cancer
- 5.5 Prostate cancer
- 5.6 Lung cancer
- 5.7 Breast cancer
- 5.8 Stomach cancer

6 Global Cancer Vaccines Market, By Technology

- 6.1 Introduction
- 6.2 Inactivated Vaccines
- 6.3 Peptide/protein vaccines
- 6.4 Synthetic Vaccines
- 6.5 Toxoid Vaccines
- 6.6 Live Attenuated Vaccines
- 6.7 Recombinant Vector Vaccines
- 6.8 Antigen vaccines
- 6.9 Dendritic Cell Vaccines
- 6.10 Subunit Vaccines
- 6.11 Heat shock protein vaccines
- 6.12 DNA- and vector-based vaccines
- 6.13 Conjugate Vaccines
- 6.14 Anti-idiotypic vaccines
- 6.15 Cancer stem cell vaccines

7 Global Cancer Vaccines Market, By End User

- 7.1 Introduction
- 7.2 Adults
- 7.3 Pediatrics

8 Global Cancer Vaccines Market, By Vaccine Type

- 8.1 Therapeutic Vaccines
- 8.2 Preventive Vaccines

9 Global Cancer Vaccines Market, By Geography

- 9.1 North America
 - 9.1.1 US
 - 9.1.2 Canada
 - 9.1.3 Mexico
- 9.2 Europe
 - 9.2.1 Germany
 - 9.2.2 France
 - 9.2.3 Italy
 - 9.2.4 UK
 - 9.2.5 Spain
 - 9.2.6 Rest of Europe
- 9.3 Asia Pacific
 - 9.3.1 Japan
 - 9.3.2 China
 - 9.3.3 India
 - 9.3.4 Australia
 - 9.3.5 New Zealand
 - 9.3.6 Rest of Asia Pacific
- 9.4 Rest of the World
 - 9.4.1 Middle East
 - 9.4.2 Brazil
 - 9.4.3 Argentina
 - 9.4.4 South Africa
 - 9.4.5 Egypt

10 Key Developments

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

11 Company Profiling

- 11.1 Oxford BioMedica
- 11.2 Vaccinogen Inc.
- 11.3 GlaxoSmithKline
- 11.4 Sanofi India Limited-P.P. Enterprises
- 11.5 Juvaris Biotherapeutics
- 11.6 Merk&co
- 11.7 Prima BioMed Ltd
- 11.8 Cytos Biotechnology AG
- 11.9 Ubivac
- 11.10 duro BioTech
- 11.11 AstraZeneca plc
- 11.12 MedImmune, LLC
- 11.13 Nova Rx Corporation
- 11.14 Argos Therapeutics
- 11.15 Prima BioMed Ltd

Complete report details @ <https://www.wiseguyreports.com/reports/674315-cancer-vaccines-global-market-outlook-2016-2022>

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.